CHESTER, N.J. and SLOUGH, England, Jan. 30 /PRNewswire/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") today announced the successful completion of its acquisition of Adams Respiratory Therapeutics, Inc. ("Adams") through a cash tender offer followed by a short- form merger of its indirect wholly owned subsidiary, Twickenham Inc., with and into Adams. As a result of this acquisition, Adams becomes an indirect wholly owned subsidiary of Reckitt Benckiser.
At the effective time of the merger, all outstanding shares of Adams common stock not validly tendered and accepted for payment in the tender offer were converted into the right to receive US$60.00 per share in cash (the same price paid in the tender offer), without interest and subject to applicable withholding of taxes. American Stock Transfer & Trust Company, acting as the paying agent for the merger, will mail to the remaining former shareholders of Adams materials necessary to exchange their former Adams shares for such payment. As a result of the merger, Adams shares will be delisted and cease to trade on the NASDAQ Global Select Market.
Notes for Editors
Reckitt Benckiser is a world leader in household cleaning, health and personal care. The Company is truly global, with over 60 operating companies and some 43 manufacturing facilities worldwide and has sales in 180 countries. Reckitt Benckiser employs 22,000 people around the world. Amongst the Company's leading brands in household are Lysol, the world leader in disinfecting cleaning, Calgonit & Finish & Electrasol, the world leaders in automatic dishwashing, Woolite, world leader in fine fabrics, Vanish & Spray'n Wash, world leaders in fabric treatment, Airwick and Mortein, both No.2 brands in air care and pest control respectively. In Health & Personal Care (25% of net revenues), leading brand positions include Veet, the world number one depilatory and Dettol the world's leading antiseptic, Nurofen, the leading European analgesic, Strepsils, world number one in medicated sore throat, Gaviscon the No.1 gastro intestinal remedy in UK and Lemsip the UK No.1 in cold/flu remedies.
Reckitt Benckiser is headquartered in Slough just outside London, UK and is listed on the London stock exchange. Reckitt Benckiser had net revenues of 4.92bn pounds, operating profit of 910m pounds, and net income of 674m pounds in 2006.
About Adams Respiratory Therapeutics, Inc.
Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.
CONTACT: Mark Wilson, Corporate Controller and Acting Head of Investor
Relations, investor queries, or Fiona Fong, Head of Corporate
Communications, press queries, both of Reckitt Benckiser, +44 0 1753 217
800; Susan Gilchrist of Brunswick, +44 0 207 404 5959, or Cindy Leggett
Flynn of Brunswick New York, +1-212-333-3810; Janet M. Barth, SVP Investor
Relations & Corporate Communications, +1-908-879-2428, or Faith
Pomeroy-Ward, Sr. Manager Investor Relations & Corporate Communications,
+1-908-879-1418, both of Adams Respiratory Therapeutics
Web site: http://www.adamsrt.com/